JP2024534420A5 - - Google Patents

Info

Publication number
JP2024534420A5
JP2024534420A5 JP2024516798A JP2024516798A JP2024534420A5 JP 2024534420 A5 JP2024534420 A5 JP 2024534420A5 JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024534420 A5 JP2024534420 A5 JP 2024534420A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/043660 external-priority patent/WO2023043923A1/en
Publication of JP2024534420A publication Critical patent/JP2024534420A/ja
Publication of JP2024534420A5 publication Critical patent/JP2024534420A5/ja
Pending legal-status Critical Current

Links

JP2024516798A 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 Pending JP2024534420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
US63/245,718 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534420A JP2024534420A (ja) 2024-09-20
JP2024534420A5 true JP2024534420A5 (cg-RX-API-DMAC7.html) 2025-08-07

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516798A Pending JP2024534420A (ja) 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用

Country Status (11)

Country Link
US (1) US20250002486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534420A (cg-RX-API-DMAC7.html)
KR (1) KR20240101555A (cg-RX-API-DMAC7.html)
CN (1) CN118434417A (cg-RX-API-DMAC7.html)
AU (1) AU2022345092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231660A1 (cg-RX-API-DMAC7.html)
IL (1) IL311458A (cg-RX-API-DMAC7.html)
MX (1) MX2024003258A (cg-RX-API-DMAC7.html)
TW (1) TW202328121A (cg-RX-API-DMAC7.html)
WO (1) WO2023043923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2594799A (en) * 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
ES2982299T3 (es) * 2016-05-31 2024-10-15 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida o sal de los mismos como inhibidores de ribonucleótido reductasa para el tratamiento del cáncer
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑
AU2018377036B2 (en) * 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
MA56065A (fr) * 2019-05-29 2022-04-06 Taiho Pharmaceutical Co Ltd Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur
EP4301735A4 (en) * 2021-03-02 2025-05-21 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2024514223A5 (cg-RX-API-DMAC7.html)
JP2024529070A5 (cg-RX-API-DMAC7.html)
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP2022505987A5 (cg-RX-API-DMAC7.html)
JP2024539946A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2022516469A5 (cg-RX-API-DMAC7.html)
JP2019529490A5 (cg-RX-API-DMAC7.html)
JP2023535453A5 (cg-RX-API-DMAC7.html)
JP2018504437A5 (cg-RX-API-DMAC7.html)
JP2023553835A5 (cg-RX-API-DMAC7.html)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2024541910A5 (cg-RX-API-DMAC7.html)
JP2015531773A5 (cg-RX-API-DMAC7.html)
JP2014510774A5 (cg-RX-API-DMAC7.html)
JP2025502943A5 (cg-RX-API-DMAC7.html)
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
JP2025513882A5 (cg-RX-API-DMAC7.html)
JP2023537271A5 (cg-RX-API-DMAC7.html)
JP2017504595A5 (cg-RX-API-DMAC7.html)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2023549494A5 (cg-RX-API-DMAC7.html)
JP2022537140A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)